These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23461599)

  • 1. Preeradication vaccine policy options for poliovirus infection and disease control.
    Thompson KM; Pallansch MA; Duintjer Tebbens RJ; Wassilak SG; Kim JH; Cochi SL
    Risk Anal; 2013 Apr; 33(4):516-43. PubMed ID: 23461599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.
    Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S398-411. PubMed ID: 25316861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.
    Kalkowska DA; Duintjer Tebbens RJ; Grotto I; Shulman LM; Anis E; Wassilak SG; Pallansch MA; Thompson KM
    J Infect Dis; 2015 Jun; 211(11):1800-12. PubMed ID: 25505296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
    Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
    Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.
    Thompson KM; Duintjer Tebbens RJ
    Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of expanding target age groups for polio immunization campaigns.
    Duintjer Tebbens RJ; Kalkowska DA; Wassilak SG; Pallansch MA; Cochi SL; Thompson KM
    BMC Infect Dis; 2014 Jan; 14():45. PubMed ID: 24472313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new polio eradication end game: rationale and supporting evidence.
    Sutter RW; Platt L; Mach O; Jafari H; Aylward RB
    J Infect Dis; 2014 Nov; 210 Suppl 1():S434-8. PubMed ID: 25316865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.
    Thompson KM; Wallace GS; Tebbens RJ; Smith PJ; Barskey AE; Pallansch MA; Gallagher KM; Alexander JP; Armstrong GL; Cochi SL; Wassilak SG
    Public Health Rep; 2012; 127(1):23-37. PubMed ID: 22298920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.
    Thompson KM; Tebbens RJ
    Expert Rev Vaccines; 2012 Apr; 11(4):449-59. PubMed ID: 22551030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of routine polio immunization in the post-certification era.
    Sutter RW; Cáceres VM; Mas Lago P
    Bull World Health Organ; 2004 Jan; 82(1):31-9. PubMed ID: 15106298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States.
    Marin M; Patel M; Oberste S; Pallansch MA
    MMWR Morb Mortal Wkly Rep; 2017 Jan; 66(1):23-25. PubMed ID: 28081056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    Modlin JF; Bandyopadhyay AS; Sutter R
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.